Activity of Cefiderocol Against Carbapenem-Resistant Clinical Isolates: a Single Center Experience.
作者信息
Quirino Angela, Cicino Claudia, Scaglione Vincenzo, Marascio Nadia, Serapide Francesca, Scarlata Giuseppe Guido Maria, Lionello Rosaria, Divenuto Francesca, La Gamba Valentina, Pavia Grazia, Russo Alessandro, Torti Carlo, Matera Giovanni, Trecarichi Enrico Maria
机构信息
Unit of Clinical Microbiology, Department of Health Sciences, "Magna Graecia" University of Catanzaro-"Mater Domini" teaching hospital; Catanzaro, Italy.
Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro - "Mater Domini" teaching hospital; Catanzaro, Italy.
出版信息
Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023043. doi: 10.4084/MJHID.2023.043. eCollection 2023.
Abstract
摘要
相似文献
1
Activity of Cefiderocol Against Carbapenem-Resistant Clinical Isolates: a Single Center Experience.
Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023043. doi: 10.4084/MJHID.2023.043. eCollection 2023.
2
Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Clinical Isolates.
Antibiotics (Basel). 2022 Jan 31;11(2):187. doi: 10.3390/antibiotics11020187.
3
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
Eur J Clin Microbiol Infect Dis. 2022 Dec;41(12):1451-1457. doi: 10.1007/s10096-022-04503-7. Epub 2022 Oct 6.
4
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849. doi: 10.1093/jac/dkaa117.
5
Activity of Cefiderocol Against , , and Endemic to Medical Centers in New York City.
Microb Drug Resist. 2020 Jul;26(7):722-726. doi: 10.1089/mdr.2019.0298. Epub 2020 Feb 7.
6
In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Strains Recovered from Clinical Samples.
Antibiotics (Basel). 2021 Oct 27;10(11):1309. doi: 10.3390/antibiotics10111309.
7
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.
8
Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Ann Transl Med. 2022 Mar;10(5):261. doi: 10.21037/atm-22-889.
9
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
J Antimicrob Chemother. 2019 Feb 1;74(2):380-386. doi: 10.1093/jac/dky425.
10
Adaptations of carbapenem resistant (CRAB) in the hospital environment causing sustained outbreak.
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001345. Epub 2021 Mar 19.
引用本文的文献
1
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant .
Microorganisms. 2025 Apr 5;13(4):829. doi: 10.3390/microorganisms13040829.
2
From Clinical Trials to Real-World Experiences: Evidence About Cefiderocol Use and Potential Role in Empirical Therapy.
Infect Dis Ther. 2025 May;14(5):897-909. doi: 10.1007/s40121-025-01147-w. Epub 2025 Apr 9.
3
Change in Diagnosis of Infection in the Treatment-Failure Era.
Antibiotics (Basel). 2024 Apr 12;13(4):357. doi: 10.3390/antibiotics13040357.
4
In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria-A Pilot Study in Bulgaria.
Antibiotics (Basel). 2024 Jan 15;13(1):81. doi: 10.3390/antibiotics13010081.
本文引用的文献
1
Is the Pendulum of Antimicrobial Drug Resistance Swinging Back after COVID-19?
Microorganisms. 2022 May 2;10(5):957. doi: 10.3390/microorganisms10050957.
2
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
Front Pharmacol. 2022 Apr 12;13:896971. doi: 10.3389/fphar.2022.896971. eCollection 2022.
3
Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Ann Transl Med. 2022 Mar;10(5):261. doi: 10.21037/atm-22-889.
4
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
5
Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital.
Microb Drug Resist. 2022 Apr;28(4):425-435. doi: 10.1089/mdr.2021.0109. Epub 2021 Dec 15.
6
In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Strains Recovered from Clinical Samples.
Antibiotics (Basel). 2021 Oct 27;10(11):1309. doi: 10.3390/antibiotics10111309.
7
In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
Pathogens. 2021 Sep 29;10(10):1258. doi: 10.3390/pathogens10101258.
8
In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Clin Microbiol Infect. 2022 Mar;28(3):447.e1-447.e6. doi: 10.1016/j.cmi.2021.07.018. Epub 2021 Jul 21.
9
In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
J Glob Antimicrob Resist. 2021 Sep;26:292-300. doi: 10.1016/j.jgar.2021.06.011. Epub 2021 Jul 15.
10
activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France.
JAC Antimicrob Resist. 2021 Jun 14;3(2):dlab081. doi: 10.1093/jacamr/dlab081. eCollection 2021 Jun.
Zotero 插件